التفاصيل البيبلوغرافية
| العنوان: |
Etomoxir, a carnitine palmitoyltransferase 1 inhibitor, combined with temozolomide reduces stemness and invasiveness in patient-derived glioblastoma tumorspheres. |
| المؤلفون: |
Shim, Jin-Kyoung, Choi, Seonah, Yoon, Seon-Jin, Choi, Ran Joo, Park, Junseong, Lee, Eun Hee, Cho, Hye Joung, Lee, Suji, Teo, Wan-Yee, Moon, Ju Hyung, Kim, Hyun Sil, Kim, Eui Hyun, Cheong, Jae-Ho, Chang, Jong Hee, Yook, Jong In, Kang, Seok-Gu |
| المصدر: |
Cancer Cell International; 10/11/2022, Vol. 22 Issue 1, p1-13, 13p |
| مصطلحات موضوعية: |
CARNITINE palmitoyltransferase, METHYLGUANINE, TEMOZOLOMIDE, FATTY acid oxidation, GLIOBLASTOMA multiforme, GENETIC overexpression |
| مستخلص: |
Introduction: The importance of fatty acid oxidation (FAO) in the bioenergetics of glioblastoma (GBM) is being realized. Etomoxir (ETO), a carnitine palmitoyltransferase 1 (CPT1) inhibitor exerts cytotoxic effects in GBM, which involve interrupting the FAO pathway. We hypothesized that FAO inhibition could affect the outcomes of current standard temozolomide (TMZ) chemotherapy against GBM. Methods: The FAO-related gene expression was compared between GBM and the tumor-free cortex. Using four different GBM tumorspheres (TSs), the effects of ETO and/or TMZ was analyzed on cell viability, tricarboxylate (TCA) cycle intermediates and adenosine triphosphate (ATP) production to assess metabolic changes. Alterations in tumor stemness, invasiveness, and associated transcriptional changes were also measured. Mouse orthotopic xenograft model was used to elucidate the combinatory effect of TMZ and ETO. Results: GBM tissues exhibited overexpression of FAO-related genes, especially CPT1A, compared to the tumor-free cortex. The combined use of ETO and TMZ further inhibited TCA cycle and ATP production than single uses. This combination treatment showed superior suppression effects compared to treatment with individual agents on the viability, stemness, and invasiveness of GBM TSs, as well as better downregulation of FAO-related gene expression. The results of in vivo study showed prolonged survival outcomes in the combination treatment group. Conclusion: ETO, an FAO inhibitor, causes a lethal energy reduction in the GBM TSs. When used in combination with TMZ, ETO effectively reduces GBM cell stemness and invasiveness and further improves survival. These results suggest a potential novel treatment option for GBM. [ABSTRACT FROM AUTHOR] |
|
Copyright of Cancer Cell International is the property of BioMed Central and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder